Neumora Therapeutics is trading 6.34% up at $0.88, with the rebound appearing to follow the recent selloff rather than a confirmed corporate catalyst.
- Shares fell 16.82% to $0.83 on September 15, 2026.
- No new company-specific announcement for September 16 has been identified.
- Recent coverage highlights earlier navacaprant trial setbacks and pipeline concerns, while broader biotech sentiment remains weak.